HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases

• DOI: 10.1007/s13277-011-0204-3
• Publication Date: 2011-08-23T19:07:33Z
• Authors: Rafael Molina; Jose M. Escudero; Jose M. Augé; Xavier Filella; Laura Foj; Aureli Torné; Jose Lejarcegui; Jaume Pahisa
• Keywords: Adult; Cancer Research; Epididymal Secretory Proteins; Risk Assessment; Young Adult; 03 medical and health sciences; 0302 clinical medicine; Reference Values; Risk Factors; Biomarkers, Tumor; Humans; Mass Screening; Aged; Aged, 80 and over; Ovarian Neoplasms; Middle Aged; 3. Good health; Postmenopause; Premenopause; ROC Curve; CA-125 Antigen; Female; Genital Diseases, Female; Algorithms; Research Article

The aim of this study is to evaluate a new tumour marker, HE4, in comparison with CA 125 and the Risk Ovarian Malignancy Algorithm (ROMA) healthy women patients benign malignant gynaecological diseases. HE4 serum levels were determined 66 women, 285 diseases (68 endometriosis, 56 myomas, 137 ovarian cysts 24 other diseases), 33 non-active cancer 143 active (111 cancers). cut-offs 35 U/mL 150 pmol/L, respectively. ROMA algorithm cut-off was 13.1 27.7 for premenopausal or postmenopausal results abnormal 1.5%, 13.6% 25.8% 1.1%, 30.2% 12.3% diseases, Among cancer, (in contrast 125) had significantly higher concentrations than malignancies (p < 0.001). Tumour marker sensitivity 79.3% 82.9% 90.1% ROMA. Both markers, related stage histological type, lowest mucinous tumours. A area under ROC curve obtained differential diagnosis versus (0.952, 0.936 0.853, respectively). Data from our population indicate that might be further improved if it used only normal (cancer risk profile 44.4%). positive similar increases specificity by 3.2% compared alone.